Gilead And AbbVie Are Not The Only Ones Re-Thinking CD47 Immunotherapies
Setback Hitting Plans For Big And Small Companies
CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.
You may also be interested in...
Survey shows long-term optimism but fears that 2024 will be another hard slog for those biotechs with dwindling cash resources.
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
Gilead’s novel immune checkpoint inhibitor candidate, magrolimab, has been placed on a partial clinical hold by the US Food and Drug Administration in acute myeloid leukemia, adding to a spate of recent setbacks for the therapy that are chipping away at investor confidence.